Announcement of Shanghai Miracle Pharmaceutical Investment Management Co., Ltd. on the plan of persons acting in concert of the controlling shareholder to reduce shareholdings

Securities code: 600613 Securities abbreviation: Miracle Pharmaceuticals Announcement number: 2026-015 900904 Miracle B shares

Shanghai Miracle Pharmaceutical Investment Management Co., Ltd.

Announcement on the controlling shareholder’s plan to reduce shareholdings by persons acting in concert

The company's board of directors, all directors and relevant shareholders guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.

Important content reminder:

 Basic information on shareholders’ shareholdings

As of the disclosure date of this announcement, Mr. Zhang Zhijun, a shareholder of Shanghai Miracle Pharmaceutical Investment Management Co., Ltd. (hereinafter referred to as the "Company"), holds 14,362,350 shares of the company, accounting for 2.69% of the company's total share capital. The above shares were acquired through agreement transfer in December 2018. Mr. Zhang Zhijun is a person acting in concert with Guizhou Magic Holding (Group) Company, the company’s controlling shareholder.

 Main contents of the shareholding reduction plan

Due to personal fund needs, Mr. Zhang Zhijun plans to reduce his holdings of the company's shares to no more than 14,362,350 shares through centralized bidding and block trading.

 This shareholding reduction plan will be implemented within 3 months after 15 trading days from the date of disclosure of this announcement, and within any consecutive 90 days, the total number of shares reduced through centralized bidding transactions on the Shanghai Stock Exchange shall not exceed 1% of the company's total shares, and the total number of shares reduced through block transactions on the Shanghai Stock Exchange shall not exceed 2% of the company's total shares.

If the above period meets the window period specified by laws, regulations and normative documents, the holding will not be reduced. If during the period of the shareholding reduction plan, the company undergoes ex-rights or ex-dividend events such as the distribution of dividends, bonus shares, conversion of capital reserves to share capital, issuance of new shares or allotment of shares, the number of shares to be reduced will be adjusted accordingly.

1. Basic situation of the holding reduction entities

Shareholder name Zhang Zhijun

Identity of shareholders Controlling shareholders, actual controllers and persons acting in concert √ Yes □ No

Shareholders who directly hold more than 5% of the shares □Yes √No

Directors, supervisors and senior managers □ Yes √ No

Others: none

Number of shares held: 14,362,350 shares

Shareholding ratio 2.69%

Source of current shareholding: Acquired through transfer agreement: 14,362,350 shares

There are persons acting in concert among the above-mentioned reduction entities:

shareholding ratio

Name of shareholder Number of shares held (shares) Examples of reasons for forming a concerted action relationship

Zhang Zhijun is the actual controller of the company Zhang Zhi Zhang Zhijun 14,362,350 2.69%

Ting's younger brother

Guizhou Magic Holdings Guizhou Magic Holdings (Group) Co., Ltd.

(Group) Co., Ltd. 90,661,620 16.98% An enterprise controlled by Zhang Zhiting, the company’s controlling shareholder and actual controller of the company Guizhou Magis Investment Guizhou Magis Investment Management Co., Ltd. 88,001,946 16.48% An enterprise controlled by Zhang Zhiting, the actual controller

Wen Bangying is the actual controller of the company Zhang Zhi Wen Bangying 24,178,700 4.53%

court wife

Total 217,204,616 40.67% —

Note: The remaining differences in the data in the above table are due to rounding.

2. Main contents of the shareholding reduction plan

Shareholder name Zhang Zhijun

The number of planned reductions shall not exceed: 14,362,350 shares

Planned shareholding reduction ratio shall not exceed: 2.69%

Method of reduction and corresponding reduction number Centralized bidding reduction, not exceeding: 5,340,716 shares Bulk transaction reduction, not exceeding: 10,681,432 shares reduction period May 28, 2026 to August 25, 2026 Source of shares to be reduced Agreement transfer

Reasons for planned reduction of holdings Personal capital needs

During the pre-disclosure period, if the company's stock is suspended from trading, the actual start time of reduction will be postponed accordingly according to the suspension time.

(1) Whether the relevant shareholders have other arrangements Yes √ No

(2) Whether major shareholders, directors, supervisors and senior management have previously made commitments on shareholding ratio, shareholding amount, shareholding period, shareholding reduction method, shareholding reduction quantity, shareholding reduction price, etc. Yes √ No

(3) Other matters required by the Exchange

None.

3. Risk warning related to shareholding reduction plan

(1) Uncertain risks in the implementation of the shareholding reduction plan, such as the prerequisites for the implementation of the plan, restrictive conditions, and the specific circumstances of the achievement or elimination of relevant conditions, etc.

During the implementation period of the shareholding reduction plan, shareholders will decide whether and how to implement the shareholding reduction plan based on market conditions, the company's stock price and other factors. There are uncertainties in the time, price, and quantity of the reduction.

(2) Whether the implementation of the shareholding reduction plan may lead to the risk of changes in the control of the listed company Yes √ No

(3) Other risk warnings

This shareholding reduction plan complies with the relevant provisions of relevant laws, regulations, departmental rules and normative documents such as the "Securities Law of the People's Republic of China", "Interim Measures for the Management of Share Reductions by Shareholders of Listed Companies", "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 15 - Reduction of Shares by Shareholders, Directors and Senior Management" and other relevant laws and regulations, departmental rules and normative documents. During the implementation of this shareholding reduction plan, the company will urge the reduction entities to strictly abide by relevant laws, regulations and regulatory requirements, and perform information disclosure obligations in a timely manner.

Announcement is hereby made.

Board of Directors of Shanghai Miracle Pharmaceutical Investment Management Co., Ltd.

May 1, 2026